2018
Health-Related Quality of Life in Patients With Progressive Midgut Neuroendocrine Tumors Treated With 177Lu-Dotatate in the Phase III NETTER-1 Trial
Strosberg J, Wolin E, Chasen B, Kulke M, Bushnell D, Caplin M, Baum RP, Kunz P, Hobday T, Hendifar A, Oberg K, Sierra ML, Thevenet T, Margalet I, Ruszniewski P, Krenning E, Group O. Health-Related Quality of Life in Patients With Progressive Midgut Neuroendocrine Tumors Treated With 177Lu-Dotatate in the Phase III NETTER-1 Trial. Journal Of Clinical Oncology 2018, 36: jco.2018.78.586. PMID: 29878866, PMCID: PMC6366953, DOI: 10.1200/jco.2018.78.5865.Peer-Reviewed Original ResearchConceptsNETTER-1 trialPhase III studyGlobal health statusHealth-related QoL.Quality of lifeMidgut NETQoL deteriorationIII studyLu-DOTATATEPhysical functioningHealth statusEuropean OrganizationTumor progressionInternational phase III studyDisease-related worriesSignificant QOL benefitsProgression-free survivalMidgut neuroendocrine tumorsNeuroendocrine tumor progressionImpact of treatmentLu-DOTATATE treatmentTreat populationQLQ CCancer QualityQOL scoresTrust in neuroendocrine tumors: The importance of communication in rare and chronic malignancies.
Mou E, Wittenberg T, Kunz P, Schapira L. Trust in neuroendocrine tumors: The importance of communication in rare and chronic malignancies. Journal Of Clinical Oncology 2018, 36: 75-75. DOI: 10.1200/jco.2018.36.7_suppl.75.Peer-Reviewed Original ResearchNeuroendocrine tumorsQuality of lifeChronic malignanciesMedical mistrustMedical community awarenessSupport group participantsPhysician-patient communicationScreening compliancePhysician-patient relationshipRare malignancyTreatment adherenceUncommon cancerCancer surveillanceTherapy recommendationsPhysician communicationClinician expertiseMEDLINE searchSymptom recognitionRare naturePatientsMeSH headingsCommunity settingsAreas of concordanceRace discordanceMalignancy
2017
Quality-of-life findings in patients with midgut neuroendocrine tumors: Results of the NETTER-1 phase III trial.
Strosberg J, Wolin E, Chasen B, Kulke M, Bushnell D, Caplin M, Baum R, Kunz P, Hobday T, Hendifar A, Oberg K, Lopera Sierra M, Kwekkeboom D, Ruszniewski P, Krenning E. Quality-of-life findings in patients with midgut neuroendocrine tumors: Results of the NETTER-1 phase III trial. Journal Of Clinical Oncology 2017, 35: 348-348. DOI: 10.1200/jco.2017.35.4_suppl.348.Peer-Reviewed Original ResearchGlobal health statusMidgut NETHealth statusHigh-dose octreotide LARNETTER-1 trialPhase III trialsProgression-free survivalEORTC QLQ-30Health-related qualityHormone-related symptomsMidgut neuroendocrine tumorsNeuroendocrine tumor progressionImpact of treatmentQuality of lifeOctreotide LARIII trialsQLQ-30Patients' QoLNeuroendocrine tumorsQOL analysisLu-DOTATATEDisease progressionLife findingsPatientsBaseline scores
2014
A phase II study of capecitabine, carboplatin, and bevacizumab for metastatic or unresectable gastroesophageal junction and gastric adenocarcinoma.
Kunz P, Nandoskar P, Koontz M, Ji H, Ford J, Balise R, Kamaya A, Rubin D, Fisher G. A phase II study of capecitabine, carboplatin, and bevacizumab for metastatic or unresectable gastroesophageal junction and gastric adenocarcinoma. Journal Of Clinical Oncology 2014, 32: 115-115. DOI: 10.1200/jco.2014.32.3_suppl.115.Peer-Reviewed Original ResearchProgression-free survivalGastroesophageal junctionStable diseaseOverall survivalPartial responseGastric adenocarcinomaPrimary endpointProgressive diseaseDay 1Response rateMedian progression-free survivalCombination of capecitabineFirst tumor assessmentBest supportive careMedian overall survivalPhase II studyPromising response ratesAddition of bevacizumabIncidence of adenocarcinomaMajor health problemQuality of lifeSecondary endpointsBaseline characteristicsFree survivalGastric cardia